|By Business Wire||
|November 9, 2012 09:02 AM EST||
XIFIN Inc., the financial cloud computing company revolutionizing the business of healthcare diagnostics from patient to payment, today announced that Rina Wolf, vice president of Commercialization Strategies, Consulting and Industry Affairs at XIFIN, Inc., will speak at the 2012 Laboratory Investment Forum, on November 15, 2012 at Bloomberg Tower in New York City.
The one-day event brings together laboratory experts to present analysis on the top market influences and key diagnostic trends impacting the clinical laboratory sector. Sessions will also cover critical topics such as laboratory stocks, growth data and investment insight on specific national labs.
Wolf will present in two sessions, including “Key Reimbursement Trends Impacting the Lab Sector,” which will highlight the logistical and financial impacts of the new molecular pathology codes being assigned to the clinical laboratory fee schedule, and “Lab Investment Opportunities and Outlook: Panel Discussion with Q&A,” evaluating critical factors driving lab investment decisions.
Wolf’s timely reimbursement session will focus on the recent announcement by The Centers for Medicare and Medicaid Services to reimburse molecular pathology tests using gap-filling beginning in 2013, and the agency’s plan to not recognize multi-analyte assays with algorithmic analyses (MAAAs) as codes valid for Medicare purposes under the CLFS in the coming year. A secondary topic will the potential impact of cuts to the most popular anatomic pathology codes.
Wolf is a leading authority and advocate in the field of laboratory commercialization and reimbursement, with over 20 years of experience in the diagnostic laboratory industry specializing in molecular diagnostic laboratories. She is a former president and board member of the California Clinical Laboratory Association and is an active participant with many industry associations, including the Personalized Medicine Coalition.
Wolf will also be a panelist for a discussion on emerging regulatory issues at the Personalized Medicine World Conference 2013, being held January 28-29, 2013 in Silicon Valley.
About XIFIN, Inc.
XIFIN delivers cloud-based revenue cycle management solutions that enable diagnostic service providers to improve cash collections and gain efficiencies that substantially improve the bottom line. XIFIN leverages its expertise and collective intelligence to deliver automation, visibility, and control through a partnership formula that ensures aligned goals, long-term focus on success, and constant attention to ongoing improvement. The company has received continual industry recognition, including being named to the Inc. 5000 fastest growing privately-held companies for the past six years, and ranking among Deloitte’s Technology Fast 500. To learn how XIFIN uniquely delivers revenue cycle management, visit www.XIFIN.com, or follow XIFIN on Twitter at www.twitter.com/#!/xifin.